RVPHOTCPharmaceutical PreparationsUS GAAP · USD

Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc. is a U.S.-based late-stage pharmaceutical company focused on discovering, developing, and seeking to commercialize new medicines for central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline centers on two internally discovered drug candidates, brilaroxazine (RP5063) and RP1208, supported by a proprietary chemistry and chemical genomics platform and a patent portfolio spanning the U.S., Europe, and other countries.

Kysy yhtiöstä
Liikevoitto (EBIT)−20,2milj. USD
+34,4 %v/v
Nettotulos−19,9milj. USD
+33,6 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−40−30−20−100milj. USD2020: EBIT −2,4 milj. USD20202021: EBIT −10 milj. USD20212022: EBIT −28 milj. USD20222023: EBIT −40 milj. USD20232024: EBIT −31 milj. USD20242025: EBIT −20 milj. USD2025−20
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Lead drug candidate development60 %

Development of brilaroxazine (RP5063) and related clinical-stage programs.

Second pipeline asset20 %

Development of RP1208 and related preclinical or clinical work.

Discovery platform10 %

Chemical genomics and proprietary chemistry used to identify new medicines.

Intellectual property10 %

Patents and patent applications protecting compounds and methods of use.

Asiakkaat

Reviva does not sell to a broad commercial customer base today; its primary counterparties are regulators, clinical trial sites, investigators, and future pharmaceutical partners or licensees. The eventual end customers for its medicines would be patients and prescribing physicians in psychiatry, inflammatory disease, and cardiometabolic care. In the near term, the business is driven by clinical development and the ability to advance candidates through regulatory review.

Regulators and approval authorities

FDA and other agencies review trial data and determine whether candidates can advance or be approved.

Clinical trial sites and investigators

Hospitals, clinics, and investigators enroll patients and generate the safety/efficacy data needed for development.

Pharmaceutical partners

Potential collaborators or licensees may support development, manufacturing, or commercialization.

Future prescribers and patients

Psychiatrists and other specialists would use approved products if the pipeline reaches market.

Strategia

Reviva’s strategy is to advance its two internally discovered drug candidates through late-stage clinical development and regulatory review, with brilaroxazine as the core program. The company also seeks to preserve and expand patent protection while securing the financing needed to complete trials and, if successful, prepare for commercialization or partnering. Its competitive position depends on generating differentiated clinical data in areas with significant unmet medical need.

Complete late-stage clinical development of brilaroxazineLyhyt aikaväli

Clinical success is the main value driver for a development-stage pharmaceutical company.

Maintain and expand intellectual property protectionKeskipitkä aikaväli

Patent exclusivity is essential to defend future commercial value and partnering leverage.

Raise capital to fund development and operationsLyhyt aikaväli

Clinical programs require ongoing funding before any product revenue can be generated.

Maantiede

Reviva is headquartered in the United States and operates as a U.S.-listed development-stage pharmaceutical company. Its intellectual property footprint extends beyond the U.S. into Europe and more than 20 foreign countries, reflecting the global scope of patent protection for its pipeline. Clinical development and eventual commercialization would likely involve multiple jurisdictions, making regulatory and patent coverage geographically important.

Riskit

Reviva faces the typical risks of a clinical-stage biotech company: trial failure, regulatory rejection, and the need for repeated external financing before commercialization. Its business is also exposed to execution risk in trial operations, third-party manufacturing, intellectual property protection, and going-concern uncertainty if capital is not raised on time.

Järjestetty vakavuuden mukaan
Clinical development failureKriittinen

Pipeline value depends on positive trial outcomes and successful progression through phases.

Kohdistuu: Brilaroxazine and RP1208

Financing and going-concern riskKriittinen

The company has no commercial product revenue and relies on external capital to fund operations.

KohdistuuEquityDebtATM issuanceCollaborations
Regulatory approval riskKorkea

FDA or other authorities may require additional data or reject applications.

Kohdistuu: U.S. and foreign jurisdictions

Manufacturing and supply chain dependenceKorkea

Clinical and future commercial supply depends on third-party manufacturers and raw materials.

Kohdistuu: Contract manufacturing and sourcing

Intellectual property protectionKorkea

Patent scope and enforceability determine the duration of competitive exclusivity.

KohdistuuBrilaroxazineRP1208Related compounds

Kirjanpito

Harkinnanvaraiset erät
Clinical trial expense recognition

Trial, regulatory, and development costs are expensed as incurred and are the main operating cost driver.

Vaikutus: Affects R&D expense and quarterly loss volatility

Fair value of warrant liabilities

Private common warrants can create non-cash gains or losses as valuation assumptions change.

Vaikutus: Can materially affect net income (loss) and volatility

Stock-based compensation

Employee and director equity awards are a meaningful non-cash expense for development-stage firms.

Vaikutus: Increases operating expenses without immediate cash outflow

Going-concern assessment

Management must evaluate whether existing cash is sufficient to fund operations for the next 12 months.

Vaikutus: Influences disclosure and investor assessment of financing risk

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

MediciNova, Inc

MNOV · Pharmaceutical Preparations

Relmada Therapeutics, Inc

RLMD · Pharmaceutical Preparations

Serina Therapeutics, Inc.

SER · Pharmaceutical Preparations

Innoviva, Inc.

INVA · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

Rezolute, Inc.

RZLT · Pharmaceutical Preparations

Päivitetty: 29.4.2026